Definitive Contract 75N93021C00044
Ended Awarded Last action
- Contract number
- 75N93021C00044
- Awardee
-
Inimmune Corp UEI EF8AMXMGG8W5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,836,453
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Pre-Solicitation · PHS20211 · Posted Jul 9, 2020
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Solicitation · Posted Jul 28, 2020
- Contract value 100% obligated
- $1,836,453.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Missoula, MT 59802, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,836,453 |
About this award
This $1.8 million firm fixed price contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Inimmune Corp. of Missoula, Montana. The contract is for Phase II of the Small Business Innovation Research program topic 091 to develop a new Toll-like receptor 4 agonist for the treatment of allergic rhinitis. The research and development effort will be performed in Missoula from September 2021 through August 2023. This total small business set-aside award was made under a broader NIH/CDC SBIR solicitation seeking innovative solutions aligned with the public health and biomedical research missions of the funding agencies.
Quick answers
Who was awarded contract 75N93021C00044?
75N93021C00044 was awarded to Inimmune Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2021.
How much is contract 75N93021C00044 worth?
The government has obligated $1,836,453 on 75N93021C00044.
Was contract 75N93021C00044 competed?
The extent of competition for 75N93021C00044 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award